Tweet
J Infect Dis. 2015 Jun 16. pii: jiv339. [Epub ahead of print]
Kinetics of hemagglutination-inhibition antibodies following maternal influenza vaccination in HIV-infected and HIV-uninfected women-infant dyads.
Nunes MC1, Cutland CL1, Dighero B2, Bate J2, Jones S1, Hugo A1, van Niekerk N1, Kuwanda L1, Izu A1, Weinberg A2, Madhi SA3; Matflu Team.
Collaborators (8)
Author information
Abstract
BACKGROUND:
We evaluated the immunogenicity of trivalent inactivated influenza vaccine (IIV3) in HIV-infected and uninfected pregnant women and the persistence of hemagglutination-inhibition (HAI) antibodies in mothers and infants.
METHODS:
Antibodies were measured pre-vaccination, one month post-vaccination, at delivery and 24 weeks post-partum in mothers and within one week of birth and at 8, 16 and 24 weeks of age in infants.
RESULTS:
We enrolled 98 HIV-uninfected and 100 HIV-infected pregnant women including 93% with ≥200 CD4+ cells/?L. Compared with HIV-uninfected, HIV-infected women had lower seroconversion rates (63%-92% vs. 36%-40%), lower antibody titers through 24 weeks post-partum, and overlapping antibody half-lives (106-121 vs. 87-153 days). Infant titers were lower than the maternal titers within one week of delivery regardless of vaccine strain and HIV-exposure status. Compared with HIV-unexposed, HIV-exposed infants had similar transplacental influenza-antibody transfer ratio; lower titers and frequency of titers ≥1:40 (82%-95% vs. 43%-79%) at birth; and higher antibody half-lives (43-45 vs. 56-65 days).
CONCLUSIONS:
Compared with HIV-uninfected, HIV-infected pregnant women had lower antibody responses and persistence thereof. Compared with HIV-unexposed, HIV-exposed infants had lower antibodies at birth, but similar after 8 weeks of life. Early IIV3 administration during pregnancy did not decrease infant birth antibody titers.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 26080370 [PubMed - as supplied by publisher]
Kinetics of hemagglutination-inhibition antibodies following maternal influenza vaccination in HIV-infected and HIV-uninfected women-infant dyads.
Nunes MC1, Cutland CL1, Dighero B2, Bate J2, Jones S1, Hugo A1, van Niekerk N1, Kuwanda L1, Izu A1, Weinberg A2, Madhi SA3; Matflu Team.
Collaborators (8)
Author information
Abstract
BACKGROUND:
We evaluated the immunogenicity of trivalent inactivated influenza vaccine (IIV3) in HIV-infected and uninfected pregnant women and the persistence of hemagglutination-inhibition (HAI) antibodies in mothers and infants.
METHODS:
Antibodies were measured pre-vaccination, one month post-vaccination, at delivery and 24 weeks post-partum in mothers and within one week of birth and at 8, 16 and 24 weeks of age in infants.
RESULTS:
We enrolled 98 HIV-uninfected and 100 HIV-infected pregnant women including 93% with ≥200 CD4+ cells/?L. Compared with HIV-uninfected, HIV-infected women had lower seroconversion rates (63%-92% vs. 36%-40%), lower antibody titers through 24 weeks post-partum, and overlapping antibody half-lives (106-121 vs. 87-153 days). Infant titers were lower than the maternal titers within one week of delivery regardless of vaccine strain and HIV-exposure status. Compared with HIV-unexposed, HIV-exposed infants had similar transplacental influenza-antibody transfer ratio; lower titers and frequency of titers ≥1:40 (82%-95% vs. 43%-79%) at birth; and higher antibody half-lives (43-45 vs. 56-65 days).
CONCLUSIONS:
Compared with HIV-uninfected, HIV-infected pregnant women had lower antibody responses and persistence thereof. Compared with HIV-unexposed, HIV-exposed infants had lower antibodies at birth, but similar after 8 weeks of life. Early IIV3 administration during pregnancy did not decrease infant birth antibody titers.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 26080370 [PubMed - as supplied by publisher]